Project Details Successful Drug Discovery - Volume II

Project No.:
Start Date:
15 November 2015
End Date:
01 May 2017
Division Name:
Chemistry and Human Health Division
Division No.:


The first volume of “Successful Drug Discovery” has been published in March 2015 by Wiley-VCH.* This second project continues to present new drug discoveries during the last decade, from established drugs to recently introduced drugs of all kinds: small-molecule-, peptide- and protein-based drugs. This will include both pioneer drugs (first in class drugs) and drug analogues (follow on drugs) in a range of therapeutic areas. The major part of the book is devoted to case histories of new drug discoveries described by their key inventors.

*See project 2013-016-1-700


The following chapters are planned:

  1. Discovery of Delamanid for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis (Hidetsugu Tsubouchi, Otsuka Pharmaceutical Co. Ltd., Japan)
  2. Discovery of Sofosbuvir for the Treatment of Hepatitis C (Michael J. Sofia, OnCore BioPharma, Dylestown, USA)
  3. Abiraterone Acetate : An Inhibitor of CYP17 as a Treatment of Prostate Cancer (Gabriel Martinez Botella, SAGE Therapeutics, Cambridge, USA)
  4. Discovery of Belinostat (Paul Finn, TopoTarget, UK)
  5. Selectivity of New Class of HDAC Inhibitor Chidamide Dictates its Immunotherapeutic Activity against Cancers (Xian-Ping Lu, Shenzen Chipscreen Biosciences, Shenzen, China)
  6. Discovery and Development of Panobinostat for Anticancer Therapy (Peter Atadja, Novartis Institutes for Biomedical Research, Shanghai, China)
  7. The Discovery and Development of Romidepsin, a Natural Product HDAC Inhibitor (A. Ganesan, University of East Anglia,Norwich, UK)
  8. The Creation of SAHA, a Pioneering Anticancer Medicine (Ronald Breslow, Columbia University, New York, USA)
  9. The Discovery of Vilazodone (Henning Boettcher, Merck KGaA, Darmstadt, Germany)
  10. Successful Drug Discovery : Nintedanib (Gerald J. Roth, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany)
  11. Development of Tridentate Chelator Deferasirox (Carsten Spanka, Novartis, Basel, Schwitzerland)
  12. Patient-Centric Design and Development of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes (Rohn Millican, Lilly Corporate Center, Indianapolis and Lilly Biotechnology Center, San Diego, USA)
  13. The Discovery of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist for Chronic Weight Management (Graeme Semple, Arena Pharmaceuticals Inc, San Diego, USA)
  14. Discovery of Vonoprazan as a Highly Potent, Long-lasting, and Novel Class of Potassium- competitive Acid Blocker (P-CAB) (Haruyuki Nishida, Takeda Pharmaceutical Company Ltd., Kanagawa, USA)


Fischer_HC_CL_LAY1b.indd Nov 2016 update – Successful Drug Discovery, Volume 2 is available:

Janos Fischer (Editor), Wayne E. Childers (Editor)
ISBN: 978-3-527-34115-3
292 pages
December 2016

Mar 2017 – Book reference announced in Chem. Int. Jan 2017, p. 28;

Page last update 17 Mar 2017